MDGN Description — Medgenics Inc
Medgenics is a clinical stage biopharmaceutical company with an emphasis on Genomic Medicine. Co. has rights to develop NFC-1, a non-stimulant metabotropic glutamate receptor (mGluR) neuromodulator for the treatment of mGluR network mutation positive Attention Deficit Hyperactivity Disorder, as well as neuropsychiatric symptoms resulting from a related rare genetic disorder, 22q11.2 Deletion Syndrome. Co. is also developing its Transduced Autologous Restorative Gene Therapy, a protein therapy that uses the patient's own skin to provide sustained production and delivery of therapeutic protein. Co. has developed the DermaVac, a proprietary harvesting device.